Literature DB >> 181491

In vitro stimulation of neutrophil motility by levamisole: maintenance of cgmp levels in chemotactically stimulated levamisole-treated neutrophils.

R Anderson, A Glover, H J Koornhof, A R Rabson.   

Abstract

Levamisole at concentrations of 10(-3) M or 10(-4) M consistently increased neutrophil random motility and chemokinesis (stimulated random migration). Similar concentrations also increased directional movement of polymorphonuclear leukocytes to both endotoxin-activated serum and hydrolyzed casein. This effect on chemotaxis was due to a true stimulation and was not due solely to increased random movement. The effect of levamisole on the neutrophils could be removed by washing, but persisted if the cells were initially treated with levamisole and serum or endotoxin-activated serum. After neutrophil stimulation with chemotactic factor an initial rise in intracellular cyclic AMP levels was detected which was not influenced by prior levamisole treatment. Intracellular cyclic GMP levels after an initial slight depression, returned to resting levels and gradually diminished over a 60-minute period. Levamisole-treated cells consistently showed higher cyclic GMP levels and it is postulated that by maintaining intracellular cyclic GMP levels, microtubular assembly and cell motility might be enhanced.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 181491

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680 in vitro.

Authors:  R Anderson; S S Visser; G Ramafi; A J Theron
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Interaction of polymorphonuclear neutrophils with Escherichia coli. Effect of enterotoxin on phagocytosis, killing, chemotaxis, and cyclic AMP.

Authors:  M J Bergman; R L Guerrant; F Murad; S H Richardson; D Weaver; G L Mandell
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

3.  Transfer factor therapy in hyperimmunoglobulinaemia E syndrome.

Authors:  H H Kesarwala; R V Prasad; R Szep; E Oldman; S Lane; P S Papageorgiou
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

4.  Human monocyte-lymphocyte interaction and its enhancement by levamisole.

Authors:  J W Kazura; W Negendank; D Guerry; A D Schreiber
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

5.  Neutrophil chemotaxis in rheumatoid arthritis. Effect of D-penicillamine, gold salts, and levamisole.

Authors:  A G Mowat
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

6.  Prevention of neutrophil chemotactic deactivation by ascorbic acid.

Authors:  F Patrone; F Dallegri; G Lanzi; C Sacchetti
Journal:  Br J Exp Pathol       Date:  1980-10

7.  A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole.

Authors:  L Businco; F Laurenti; P Rossi; E Galli; F Aiuti
Journal:  Arch Dis Child       Date:  1981-01       Impact factor: 3.791

8.  Effect of levamisole on lysosomal enzyme release from polymorphonuclear leukocytes and intracellular levels of cAMP and cGMP after phagocytosis of monosodium urate crystals.

Authors:  D Mikulíková; K Trnavský
Journal:  Agents Actions       Date:  1980-09

9.  Potentiation and inhibition of migration of human neutrophils by auranofin.

Authors:  J G Elferink; B M de Koster
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

10.  Effects of levamisole on normal and abnormal leukocyte locomotion.

Authors:  D G Wright; C H Kirkpatrick; J I Gallin
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.